Recombinant Orancistrocerus drewseni Eumenine mastoparan-OD (VP1)

What is Eumenine mastoparan-OD and how was it first isolated?

Eumenine mastoparan-OD is a novel biologically active peptide isolated from the solitary wasp, Orancistrocerus drewseni drewseni (Eumeninae, Vespidae). The peptide was first identified through MALDI-TOF MS analysis of crude venom, which revealed molecular-related ion peaks at m/z 1269.9, indicating a previously uncharacterized compound. The isolation methodology involved initial HPLC purification of crude venom to separate distinct peptide fractions. The amino acid sequence was subsequently determined through complementary analytical techniques including ESI-MS/MS, automated Edman degradation, and amino acid analysis, confirming its 15-amino acid sequence (GRILSFIKAGLAEHL-NH2). Researchers conducting preliminary investigations should note that this peptide demonstrates significant homology with other mastoparans but possesses unique structural features that contribute to its enhanced biological activity .

What is the structural relationship between Eumenine mastoparan-OD and other wasp venom peptides?

Eumenine mastoparan-OD belongs to the broader family of mastoparan peptides, which are among the most abundant components in hunting wasp venoms. While traditional mastoparans are tetradecapeptides (14 amino acids), Eumenine mastoparan-OD is a pentadecapeptide (15 amino acids), representing a structural variation. All mastoparans share characteristic structural features, including an amphiphilic α-helix structure and a net positive charge. In this configuration, all hydrophobic amino acid side chains are positioned on one side of the structure, while basic or hydrophilic amino acid residues are arranged on the opposite side. This amphipathic arrangement is critical for their biological function, as it enables the peptides to attach to biological membranes and form pores, thereby increasing cell membrane permeability. Researchers should recognize that this structural motif is conserved across various mastoparan peptides despite sequence variations, forming the basis for their common biological activities .

How does Eumenine mastoparan-OD compare with Orancis-Protonectin from the same wasp species?

Eumenine mastoparan-OD (GRILSFIKAGLAEHL-NH2) and Orancis-Protonectin (ILGIITSLLKSL-NH2) represent two distinct bioactive peptides isolated from the same solitary wasp species, Orancistrocerus drewseni drewseni. These peptides differ significantly in their amino acid sequences and length, with mastoparan-OD being a 15-residue peptide and Orancis-Protonectin containing 12 amino acids. Notably, Orancis-Protonectin represents the first example of a protonectin analog isolated from a solitary wasp's venom, making it particularly significant from an evolutionary perspective. While both peptides demonstrate hemolytic activity, comparative assays reveal that Eumenine mastoparan-OD and Orancis-Protonectin exhibit more potent hemolytic properties than conventional mastoparan, suggesting enhanced membrane-disrupting capabilities. The identification of both peptides from the same species provides valuable insight into the diversity of venom components within individual wasp species and their potentially complementary biological roles in envenomation .

What are the primary biological activities of mastoparan peptides?

Mastoparan peptides, including Eumenine mastoparan-OD, exhibit diverse biological activities that stem from their interactions with cellular membranes and signaling systems. Their primary activities include:

• Mast cell degranulation: Mastoparans trigger the release of inflammatory mediators from mast cells, contributing to localized inflammation. This process can occur through direct interaction with G proteins without receptor association, leading to granule exocytosis.

• Hemolytic activity: These peptides can bind to erythrocyte membranes, creating pores that lead to cell lysis. The hemolytic activities of Eumenine mastoparan-OD and Orancis-Protonectin have been demonstrated to be more potent than that of conventional mastoparan.

• Antimicrobial properties: Mastoparans generally exhibit stronger activity against fungi than against Gram-negative bacteria, making them potential templates for novel antimicrobial compounds.

• Cell-specific effects: The biological impact varies by cell type. Mastoparan exposure causes histamine release from mast cells, serotonin release from platelets, insulin release from pancreatic β-cells, and catecholamine release from chromaffin cells.

• Cytotoxicity: Mastoparans can increase tumor cell cytotoxicity, alter mitochondrial permeability, and impair cell viability, potentially leading to necrosis and/or apoptosis through the activation of phospholipases A, C, and D, and calcium mobilization from intracellular stores .

What basic experimental approaches are used to measure the hemolytic activity of mastoparan peptides?

Measuring the hemolytic activity of mastoparan peptides typically involves standardized assays using fresh erythrocyte preparations. The general methodology includes:

• Erythrocyte preparation: Fresh blood (typically from healthy human donors or standard laboratory animals) is collected with anticoagulants, washed multiple times with PBS (phosphate-buffered saline), and standardized to specific concentrations (usually 2-4%).

• Hemolysis assay: Standardized erythrocyte suspensions are incubated with increasing concentrations of the peptide (typically 1-100 μM) at physiological temperature (37°C) for a defined period (30-60 minutes).

• Measurement of hemoglobin release: After incubation, samples are centrifuged, and the supernatant is collected for spectrophotometric analysis. Hemoglobin release is measured by absorbance readings at 540-550 nm.

• Data analysis: The percentage of hemolysis is calculated relative to positive (100% lysis with a detergent like Triton X-100) and negative (buffer only) controls. The HC50 value (concentration causing 50% hemolysis) is determined from dose-response curves.

This standardized approach allows direct comparison between different mastoparan variants, such as the observation that Eumenine mastoparan-OD and Orancis-Protonectin demonstrate more potent hemolytic activities compared to conventional mastoparan .

What are the molecular mechanisms of mastoparan peptides' interactions with G proteins?

Mastoparan peptides, including Eumenine mastoparan-OD, interact with heterotrimeric G proteins through complex mechanisms that bypass traditional receptor-mediated activation. The molecular interactions involve:

• Direct G protein binding: Mastoparans directly interact with G protein α-subunits, particularly those of the Gi and Go families, which are typically ADP-ribosylated by pertussis toxin (PTX). This interaction occurs through the amphipathic α-helical structure of the peptide mimicking activated G protein-coupled receptors.

• Receptor-independent activation: Unlike physiological activation, mastoparan peptides can stimulate G protein activity without the involvement of cell surface receptors, representing a form of direct G protein modulation.

• Differential sensitivity to bacterial toxins: Interestingly, some mastoparan effects show selective modification by specific bacterial toxins. For example, studies in PC12 cells demonstrated that mastoparan-stimulated noradrenaline release was inhibited by cholera toxin (CTX) pretreatment rather than by pertussis toxin (PTX), suggesting involvement of Gs rather than Gi/Go proteins in certain cellular contexts.

• Modulation of cyclic AMP signaling: Mastoparan can inhibit forskolin-stimulated cyclic AMP accumulation in a dose-dependent manner, with higher concentrations (20 μM) maintaining inhibitory effects even after PTX pretreatment. This indicates both PTX-sensitive and PTX-insensitive mechanisms of action.

• Interaction with ADP-ribosylation factors (ARF): Mastoparan has been shown to inhibit CTX-catalyzed ADP-ribosylation of various proteins, including ARF, suggesting a direct interaction with this critical component of vesicular trafficking machinery .

These complex interactions with cellular signaling systems explain the diverse and sometimes cell-type-specific effects of mastoparan peptides, providing multiple potential targets for therapeutic applications or research tools.

How do researchers synthesize and purify recombinant Eumenine mastoparan-OD for experimental applications?

The synthesis and purification of recombinant Eumenine mastoparan-OD for research applications involve several sophisticated methodological approaches:

• Solid-phase peptide synthesis (SPPS): The most common approach for obtaining synthetic mastoparan peptides involves Fmoc (9-fluorenylmethoxycarbonyl) chemistry, which allows for the sequential addition of protected amino acids to build the GRILSFIKAGLAEHL sequence. C-terminal amidation, critical for biological activity, is achieved using specialized resins.

• Recombinant expression systems: For larger-scale production, researchers employ bacterial expression systems (typically E. coli) with specialized vectors containing fusion partners (e.g., SUMO, thioredoxin, or GST) to overcome the inherent toxicity of the peptide to the host cells. The gene sequence is optimized for codon usage in the expression host.

• Fusion protein design: The peptide is typically expressed as a fusion with a larger protein to decrease toxicity and increase expression levels. A precision protease cleavage site (such as TEV or Factor Xa) is incorporated between the fusion partner and the mastoparan sequence.

• Purification protocol:

  • Initial capture using affinity chromatography based on the fusion tag

  • Proteolytic cleavage to release the mastoparan peptide

  • Reverse-phase HPLC purification to separate the peptide from the fusion partner

  • Final verification using mass spectrometry (MALDI-TOF or ESI-MS) to confirm the correct molecular weight of 1269.9 Da

• Quality control: The purified peptide undergoes circular dichroism (CD) spectroscopy to verify proper α-helical secondary structure formation in membrane-mimicking environments, which is essential for biological activity.

This methodological approach ensures the production of highly pure recombinant Eumenine mastoparan-OD suitable for detailed structure-function studies and therapeutic development .

How does the conformation of Eumenine mastoparan-OD change in different membrane environments?

The conformational behavior of Eumenine mastoparan-OD in various membrane environments represents a critical aspect of its functional mechanism and can be characterized through several biophysical techniques:

Understanding these conformational dynamics is essential for rationalizing the structure-activity relationships of Eumenine mastoparan-OD and for designing peptide analogs with enhanced specificity or reduced toxicity .

What experimental models are most appropriate for studying mastoparan-OD's effects on specific cell types?

When investigating the cellular effects of Eumenine mastoparan-OD, researchers should select experimental models based on the specific biological process under study:

• Mast cell degranulation studies:

  • Primary cultures of rat peritoneal mast cells or human skin mast cells provide physiologically relevant systems.

  • The RBL-2H3 rat basophilic leukemia cell line serves as a well-characterized model for quantitative assessment of degranulation via β-hexosaminidase or histamine release assays.

  • Fluorescent calcium indicators (Fura-2 or Fluo-4) can be employed to monitor intracellular calcium mobilization, which precedes degranulation.

• Neuronal secretion models:

  • PC12 cells (derived from rat pheochromocytoma) offer a robust model for studying catecholamine release, as demonstrated in studies showing mastoparan stimulates [³H]noradrenaline release in a calcium-independent manner, unlike high K⁺ or ATP stimulation which require calcium.

  • Primary cultures of chromaffin cells provide a more physiologically relevant system for studying exocytosis mechanisms.

• G-protein interaction studies:

  • Membrane preparations from cells expressing defined G-protein subtypes allow for specific binding and activation assays.

  • [³⁵S]GTPγS binding assays provide direct measurement of G-protein activation.

  • FRET-based assays using fluorescently labeled G-protein subunits enable real-time monitoring of conformational changes.

• Antimicrobial activity assessment:

  • Standard minimum inhibitory concentration (MIC) assays using clinically relevant bacterial and fungal strains.

  • Time-kill kinetics to assess the rate of microbial death.

  • Membrane permeabilization assays using fluorescent dyes like propidium iodide or SYTOX Green.

• Cytotoxicity and specificity studies:

  • Primary human erythrocytes for hemolytic activity.

  • Normal mammalian cell lines (HEK293, NIH/3T3) versus cancer cell lines (HeLa, MCF-7) to assess differential cytotoxicity.

  • 3D cell culture models that better recapitulate tissue architecture for more predictive toxicity assessment.

The selection of appropriate experimental models should consider the balance between physiological relevance and experimental tractability, with primary cell cultures offering greater relevance and established cell lines providing better reproducibility and throughput .

How does mastoparan-OD influence calcium mobilization in target cells?

Eumenine mastoparan-OD exerts profound effects on cellular calcium homeostasis through multiple mechanisms that contribute to its biological activity:

Understanding these calcium mobilization mechanisms is crucial for interpreting the cellular effects of mastoparan-OD and for developing strategies to modulate its activity for potential therapeutic applications .